Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients
| العنوان: | Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients |
|---|---|
| المؤلفون: | Kurland, Lisa, Melhus, Håkan, Karlsson, Julia, Kahan, Thomas, Malmqvist, Karin, Öhman, K. Peter, Nyström, Fredrik, Hägg, Anders, Lind, Lars |
| المصدر: | Journal of Hypertension. 19(10):1783-1787 |
| مصطلحات موضوعية: | Adrenergic beta-Antagonists/therapeutic use, Antihypertensive Agents/*therapeutic use, Atenolol/therapeutic use, Biphenyl Compounds/*therapeutic use, Blood Pressure/*drug effects, Double-Blind Method, Female, Forecasting, Humans, Hypertension/*drug therapy/*genetics, Male, Middle Aged, Peptidyl-Dipeptidase A/*genetics, Polymorphism, Genetic/*physiology, Receptor, Angiotensin, Type 1, Receptors, Angiotensin/*antagonists & inhibitors, Research Support, Non-U.S. Gov't, Tetrazoles/*therapeutic use, Treatment Outcome, MEDICINE, MEDICIN |
| الوصف: | OBJECTIVES: To determine whether polymorphisms in the renin-angiotensin system can predict blood pressure-lowering response to antihypertensive treatment; more specifically, in response to treatment with irbesartan or atenolol. DESIGN AND METHODS: Eighty-six patients with hypertension were randomized to double-blind treatment with either the angiotensin II type 1 receptor antagonist irbesartan or the beta1 adrenergic receptor blocker atenolol and followed for 3 months. We analysed angiotensinogen T174M and M235T, angiotensin converting enzyme (ACE) I/D and angiotensin II type 1 receptor A1166C polymorphisms and related them to blood pressure reduction. RESULTS: The mean reductions in blood pressure were similar for both treatments. In the irbesartan group, individuals homozygous for the ACE gene I allele showed a greater reduction in diastolic blood pressure, exceeding those with the D allele (-18 +/- 11 SD versus -7 +/- 10 mmHg, P = 0.0096). This was not the case during treatment with atenolol, and the interaction term between type of treatment and ACE II genotype was significant (P = 0.0176). The angiotensinogen and angiotensin II type 1 receptor polymorhisms were not related to the response to treatment. CONCLUSIONS: ACE genotyping predicted the blood pressure-lowering response to antihypertensive treatment with irbesartan but not atenolol. Thus, specific genotypes might predict the response to specific antihypertensive treatment. |
| وصف الملف: | |
| الوصول الحر: | https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-73122Test http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11593098&dopt=CitationTest |
| قاعدة البيانات: | SwePub |
| تدمد: | 02636352 14735598 |
|---|